The trial on a vaccine developed by the University of Oxford in Britain and the group “AstraZeneca” for drugs has already resumed in the United States after a break of more than six weeks in the country.
The other experiment is being conducted by the “Johnson & Johnson” group, and it will soon return after obtaining the green light from an independent committee that studied a mysterious disease that a participant contracted in October.
Ten European, American, Chinese and Russian vaccines are being tested on a large scale in the world, with the participation of tens of thousands of volunteers in each of them, to verify their effectiveness and non-danger.
And regulators fear vaccines could have dangerous side effects. When one of the participants becomes ill, the experiments are suspended to verify whether it was caused by the vaccine or not.
As for the experimental “AstraZeneca / Oxford” vaccine, Britain concluded after a few days that it was safe and allowed the resumption of experiments. South Africa, Brazil and Japan followed suit.
In the United States, the authorities maintained a state of suspense without any explanation. The experiments were suspended on the sixth of September.
AstraZeneca said that the US Drug and Drug Administration (FDA) had allowed the trial to resume in the United States after it had been repeated in other countries in recent weeks. The agency studied all global trial safety data and concluded that the trials could be safely resumed.
The results of this experiment are expected to be released during the current year, as confirmed by the group, although this depends on the pace of the epidemic in the country in which the vaccine is being tested.
And many countries rely on this vaccine. AstraZeneca has already sold hundreds of millions of doses on several continents and signed partnerships with other producers to produce the doses locally, with orders expected to reach several billions.
– Vaccinate before the New Year? – Johnson & Johnson announced that an independent committee recommended the resumption of the third phase experiment with the participation of 60,000 people, which began at the end of September.
The group explained, “After an in-depth evaluation of a dangerous health symptom in one of the participants, no definite reason was identified for this. The company did not find any evidence that the experimental vaccine caused this.”
Among the advantages of this vaccine is that it is limited to one dose instead of two doses, as is the case with most of the other competing vaccines, which earns the evaluation efforts three to four weeks.
“If all goes well, we expect the experiment to advance quickly,” said US official Paul Mango.
These were the details of the news Kuwait – A green light to resume trials of two vaccines... for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at saudi24news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.